DuPont de Nemours Inc
For the period ended Mar 31, 2025. Filed May 2, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 2, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Supplementary Information
NOTE 7 -SUPPLEMENTARY INFORMATION
| Sundry Income (Expense) - Net | Three Months Ended March 31, | |
|---|---|---|
| In millions | 2025 | 2024 |
| Non-operating pension and other post-employment benefit credits | $3 | $7 |
| Interest income 1 | 21 | 20 |
| Net gain on divestiture and sales of other assets and investments | — | 2 |
| Foreign exchange (losses) gains, net | (3) | 4 |
| Interest rate swap gain 2 | 78 | — |
| Miscellaneous income (expense) - net | 2 | 5 |
| Sundry income (expense) - net | $101 | $38 |
The three months ended March 31, 2025 and 2024 include interest on cash and marketable securities. Fluctuations in interest income are due to changes in cash balances and/or changes in interest rates.
Includes the non-cash mark-to-market gain related to the 2022 Swaps and 2024 Swaps offset by the interest settlement loss on the 2022 Swaps. Refer to Note 19 for further details.
Cash, Cash Equivalents and Restricted Cash
At March 31, 2025 and December 31, 2024, the Company had $5 million and $6 million, respectively, within “Restricted cash and cash equivalents” in the interim Condensed Consolidated Balance Sheets. At March 31, 2025 and December 31, 2024, the Company also had $36 million within "Restricted cash and cash equivalents - noncurrent". The majority of the balance as of March 31, 2025 is attributable to the MOU cost sharing arrangement. Additional information can be found in Note 14.
Accrued and Other Current Liabilities
"Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets were $947 million at March 31, 2025 and $1,031 million at December 31, 2024. Accrued payroll, which is a component of "Accrued and other current liabilities," was $246 million at March 31, 2025 and $383 million at December 31, 2024. No other component of "Accrued and other current liabilities" was more than 5 percent of total current liabilities at March 31, 2025 and at December 31, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.